Treatment of perinatal mood and anxiety disorders: A review

被引:58
作者
Misri, Shaila
Kendrick, Kristin
机构
[1] St Pauls Hosp, Reproduct Mental Hlth Program, Vancouver, BC V6Z 1Y6, Canada
[2] British Columbia Womens Hosp, Vancouver, BC V6Z 1Y6, Canada
[3] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
来源
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE | 2007年 / 52卷 / 08期
关键词
perinatal; pregnancy; postpartum; depression; anxiety; pharmacologic; nonpharmacologic; treatment;
D O I
10.1177/070674370705200803
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objectives: To review the nonpharmacologic and pharmacologic treatment modalities for perinatal mood and anxiety disorders and to discuss the importance of weighing the risks and the benefits of exposing the fetus or baby to maternal mental illness as opposed to exposure to antidepressant medications. Methods: We conducted a literature search of the PubMed and MEDLINE databases. Key words included the following: perinatal, pregnancy, postpartum, depression, anxiety, pharmacologic, nonpharmacologic, psychotherapy, and treatment. Results: Recent literature reflects that both pharmacologic and nonpharmacologic treatments for perinatal women are associated with positive and negative outcomes. No treatment decision was found to be risk-free. The detrimental effects of untreated mental illness on the mother, as well as on the baby, highlight the need for treatment intervention. The long-term effects of exposure to either medications or maternal mental illness are unknown, as yet. Conclusion: Women with perinatal depression and anxiety disorders require timely and efficient management with a goal of providing symptom relief for the suffering mother while simultaneously ensuring the baby's safety. Although knowledge in the area of appropriate intervention is constantly evolving, rigorous and scientifically sound research in the future is critical.
引用
收藏
页码:489 / 498
页数:10
相关论文
共 113 条
[1]  
Altshuler LL, 1996, AM J PSYCHIAT, V153, P592
[2]  
*AM COLL OBST GYN, 2006, OBSTET GYNECOL, V108, P1601
[3]   Neonatal outcome following maternal antenatal depression and anxiety:: A population-based study [J].
Andersson, L ;
Sundström-Poromaa, I ;
Wulff, M ;
Åström, M ;
Bixo, M .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 159 (09) :872-881
[4]   A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression [J].
Appleby, L ;
Warner, R ;
Whitton, A ;
Faragher, B .
BRITISH MEDICAL JOURNAL, 1997, 314 (7085) :932-936
[5]  
AUSTIN MP, 2006, PSYCHOL MED, P1
[6]   Serum bupropion levels in 2 breastfeeding mother-infant pairs [J].
Baab, SW ;
Peindl, KS ;
Piontek, CA ;
Wisner, KL .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (10) :910-911
[7]   Paroxetine in human milk [J].
Begg, EJ ;
Duffull, SB ;
Saunders, DA ;
Buttimore, RC ;
Ilett, KF ;
Hackett, LP ;
Yapp, P ;
Wilson, DA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (02) :142-147
[8]   Breastfeeding during maternal antidepressant treatment with serotonin Reuptake inhibitors: Infant exposure, clinical symptoms, and cytochrome P450 genotypes [J].
Berle, JO ;
Steen, VM ;
Aamo, TO ;
Breilid, H ;
Zahlsen, K ;
Spigset, O .
JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (09) :1228-1234
[9]  
Briggs G., 1998, DRUGS PREGNANCY LACT, V5th
[10]   The use of psychotropic medications during breast-feeding [J].
Burt, VK ;
Suri, R ;
Altshuler, L ;
Stowe, Z ;
Hendrick, VC ;
Muntean, E .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (07) :1001-1009